Raltegravir

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Isentress · 2.2, Table 1

• • Always with other antiretrovirals (unless a complete regimen). FDA Isentress · 2.2
• • With rifampin: 800 mg twice daily. Chewable tablets and suspension are not interchangeable with film-coated tablets. FDA Isentress · 2.2, Table 1FDA Isentress · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: Antiretroviral Pregnancy Registry data show no difference from the background birth-defect rate. FDA Isentress · 8.1

  “Available data from the APR show no difference in the rate of overall birth defects for raltegravir compared to the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP).”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Isentress · 8.2

  “Risk Summary The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Isentress · 8.4

  “ISENTRESS HIV-1 Infected Children The safety, tolerability, pharmacokinetic profile, and efficacy of twice daily ISENTRESS were evaluated in HIV-1 infected infants, children and adolescents 4 weeks to 18 years of age in an open-label, multicenter clinical trial, IMPAACT P1066 [see Dosage and Administration (2.3) , …”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Isentress · 8.5

  “In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.